Advancing Regenerative Medicine
The current portfolio of regenerative medicine technologies, which derive from discovery science at four Canadian laboratories, offer new hope in the areas of spinal cord repair, diabetes and cardiovascular disease.
Securing global patent rights, which can prove cost-prohibitive for some individual research institutions, is part of Aggregate’s strategy to derive greater value from Canadian science.
“The structure of Aggregate Therapeutics represents a radically new commercialization model that allows investors to quickly identify the most innovative convergent technologies by offering them a central point to access early intellectual property,“ said Dr. Freda Miller, Senior Scientist at The Hospital for Sick Children Research Institute and founder of Aegera Therapeutics Inc. “I’m most impressed by the energy and commitment that MaRS has demonstrated for this project in such a short time.”
Established in mid-2005, Aggregate is dedicated to developing the discoveries of 37 leading Canadian scientists working at 16 academic institutions.
For more information, visit www.aggregatetx.com
BROWSE PAGES
- MaRS Convergence: Spring 2008
- MaRS Convergence: Fall 2007
- Artists Converge at MaRS, too
- Flagship Program Supported
- Advancing Regenerative Medicine
- Governator Pumps Up Research
- Pain Research Attracts Financing
- Not Just a Pretty Façade
- Phase II: MaRS Goes Global
- Toronto Lures Florida
- Venture Capital Moves to MaRS
- Tenant Profile: Octopz
- Social Innovation Network to be Anchored at MaRS
- MaRS Convergence: Winter 2006/07
- MaRS Convergence: Fall 2006
- MaRS Convergence: Winter 2005
